Core Insights - The expiration of the compound patent for Pyraclostrobin in China has led to a surge in domestic interest, with companies increasing registration, production, and promotion efforts [1][6] - As of 2024, there are 62 registered Pyraclostrobin products in China, including 32 active ingredients and 30 formulations, primarily targeting wheat and peanut crops [1][6] - The global market for Pyraclostrobin has seen significant growth, with sales expected to rise from $973 million in 2015 to $2.014 billion by 2024, and projected to reach $2.172 billion by 2025 [5][11] Industry Overview - Pyraclostrobin, developed by Bayer in 2004, is a broad-spectrum fungicide known for its low toxicity and effectiveness against various plant diseases [2][3] - It is particularly effective against diseases affecting cereals and legumes, making it a key product in the global fungicide market, holding an 8% market share [3][5] Market Dynamics - The Chinese market for Pyraclostrobin is expanding rapidly due to the high incidence of wheat diseases, particularly Fusarium head blight, which can cause yield losses of 10% to 20% in epidemic years [7][11] - The area affected by Fusarium head blight in China is projected to reach 15 million acres in 2024, an increase of 6 million acres from 2023 [7][8] Competitive Landscape - Major companies in the Pyraclostrobin sector include Hailir, Anhui Jiuyi, Nantong Taihe, and Guangdong Guokang, among others, with many expanding production capacity [9][10] - Hailir reported a revenue of 3.391 billion yuan in the first nine months of 2025, a 5.5% increase year-on-year, indicating strong market performance [10] Future Trends - The demand for Pyraclostrobin is expected to continue rising due to increasing occurrences of wheat diseases and advancements in application methods [11] - The market is becoming increasingly competitive, with potential oversupply leading to price fluctuations, necessitating companies to optimize production and enhance brand presence [12] - The trend towards formulation mixtures is anticipated to grow, as combining Pyraclostrobin with other chemicals can delay resistance development and enhance efficacy [13]

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Viewpoints - The report highlights the impact of the recent cancellation and reduction of export tax rebates on pesticides, particularly focusing on the potential for price increases and improved profitability for leading companies in the pesticide sector [5] - The report anticipates a reversal in the pesticide industry's performance due to rising export costs and the upcoming spring farming season, which is expected to boost demand and prices [5] - The ongoing "anti-involution" trend in the pesticide industry is expected to optimize supply and reshape value, encouraging companies to shift from low-end manufacturing to a focus on technology, branding, and service [5] Summary by Relevant Sections Industry Overview - The pesticide industry is experiencing a significant shift due to policy changes, with the cancellation of export tax rebates for various pesticide raw materials and intermediates, including glyphosate and other high-toxicity products [4][5] - China is projected to export 2.05 million tons of pesticides in 2024, with exports accounting for 90% of production [5] Market Dynamics - The domestic pesticide production peak season occurs from February to May, with a significant increase in demand for pesticide formulations during this period [5] - The report notes that the price of 95% glyphosate raw powder has recently increased to 46,000 yuan per ton, indicating a recovery in pricing [11] Key Companies and Recommendations - Recommended stocks include leading pesticide companies such as Yangnong Chemical, Limin Co., and Xingfa Group, which are expected to benefit from the price increases and the integrated "raw material-formulation" model [5] - Beneficiary stocks also include Jiangshan Chemical, Lier Chemical, and others involved in various segments of the pesticide supply chain [5]

1月15日，上海悦联与日本曹达携手推出的国内首款抗性白粉防治新品日曹®悦百定®，全国上市会暨田间观摩会在云南昆明盛大召开。凭借日本曹达独 家化合物环氟菌胺的创新作用机理，结合上海悦联米家纳米微乳制剂工艺的技术赋能，这款"快速收粉、靓叶美果"的方案型产品，为国内白粉防治市场带 来新选择。全国重点经销商及日本曹达的嘉宾们齐聚一堂，共同见证了这一里程碑时刻。 技术创新显成效，合作共赢破困局 日曹®悦百定®的成功上市正是源于两大核心技术的突破：日本曹达的独家化合物环氟菌胺和上海悦联的纳米微乳制剂工艺。 日本曹达中国总经理前川贵裕表示，上海悦联在制剂工艺的升级和研发投入方面给他留下了深刻的印象。作为曾在日本曹达参与制剂研发的专家，他对技 术创新的高要求有着独到的见解。在纳米微乳技术领域，上海悦联取得了显著成果，这项技术的成功应用，使得日本曹达的独家化合物在中国市场的落地 得到了更好的支持。 前川贵裕高度评价双方的合作成果，认为这一技术不仅提高了产品的利用度和稳定性，还有效促进了市场推广。他对未来的合作充满信心，相信日曹悦百 定®将在中国市场取得成功，并为农药行业带来更多的创新和价值。 据悉，环氟菌胺是日本曹达独家化合物 ...

Core Viewpoint - The company, Shaoxing Baismei Chemical Co., Ltd., is expected to achieve a net profit attributable to shareholders of 23.68 million to 34.06 million yuan in 2025, marking a turnaround from losses to profits, with significant improvements in operational quality [1] Group 1: Financial Performance - The projected net profit for 2025 represents a significant improvement compared to previous years, with a non-recurring net profit expected to be between 19.06 million and 27.37 million yuan [1] - The company is focusing on structural adjustments and management optimization to enhance its financial performance amidst a complex market environment [1] Group 2: Business Strategy - Baismei is implementing a "strong chain, extended chain" strategy to optimize and upgrade its product structure, with notable contributions from trade-related products to the positive net profit [1] - The company is increasing its investment in research and development to support the development of efficient and low-risk new chemical pesticides, aligning with national policies and market demands for green chemicals [2] Group 3: Internal Management - The company is emphasizing refined management throughout its operations, promoting digital and intelligent upgrades to enhance operational efficiency and strengthen cost and risk control [1] - High standards in safety, environmental protection, and compliance are maintained to ensure stable operations and sustainable development [1]

Core Viewpoint - Guangxin Co., Ltd. has experienced fluctuations in stock performance and financial metrics, with a notable decrease in revenue and net profit year-on-year, while maintaining a significant presence in the agricultural chemicals sector [1][2]. Group 1: Stock Performance - On January 15, Guangxin's stock rose by 3.04%, with a trading volume of 221 million yuan [1]. - The margin trading data indicated a financing buy of 15.46 million yuan and a repayment of 37.14 million yuan, resulting in a net financing outflow of 21.68 million yuan [1]. - As of January 15, the total margin trading balance for Guangxin was 336 million yuan, with the financing balance accounting for 3.02% of the circulating market value, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Guangxin reported a revenue of 2.663 billion yuan, reflecting a year-on-year decrease of 23.69% [2]. - The net profit attributable to shareholders was 520 million yuan, down 9.36% compared to the previous year [2]. - Since its A-share listing, Guangxin has distributed a total of 2.503 billion yuan in dividends, with 1.442 billion yuan distributed over the last three years [2]. Group 3: Shareholder Information - As of September 30, 2025, Guangxin had 19,100 shareholders, an increase of 24.31% from the previous period [2]. - The average number of circulating shares per shareholder was 47,778, which decreased by 19.56% compared to the last period [2]. - Notable institutional shareholders include招商核心竞争力混合A and 华夏行业景气混合A, with stable holdings, while 香港中央结算有限公司 increased its holdings by 2.6877 million shares [2].

Group 1 - The core viewpoint of the news is that Limin Co., Ltd. has shown significant financial performance and trading activity, with a notable increase in net profit and a stable financing situation [1][2] Group 2 - On January 15, Limin Co., Ltd. saw a stock price increase of 2.03%, with a trading volume of 493 million yuan. The financing buy-in amount for the day was 99.19 million yuan, while the financing repayment was 43.02 million yuan, resulting in a net financing buy-in of 56.18 million yuan [1] - As of January 15, the total financing and securities balance for Limin Co., Ltd. was 426 million yuan, which accounts for 5.24% of its circulating market value [1] - The company had no shares repaid in the securities lending market on January 15, with 100 shares sold, amounting to 1,710 yuan at the closing price, and a remaining securities lending balance of 900 shares valued at 15,400 yuan [1] Group 3 - As of December 31, the number of shareholders for Limin Co., Ltd. was 56,100, a decrease of 2.03% from the previous period, while the average circulating shares per person increased by 10.12% to 7,747 shares [2] - For the period from January to September 2025, Limin Co., Ltd. achieved an operating income of 3.599 billion yuan, representing a year-on-year growth of 7.62%, and a net profit attributable to shareholders of 390 million yuan, which is a remarkable increase of 661.66% [2] - Since its A-share listing, Limin Co., Ltd. has distributed a total of 918 million yuan in dividends, with 321 million yuan distributed over the past three years [2]

Core Viewpoint - The recent cancellation of certain pesticide export tax rebates signals a shift in China's agricultural chemical industry towards high-quality development, moving away from low-price competition based on subsidies [1][4]. Group 1: Policy Impact on Pesticide Industry - The policy adjustment targets the "involution" phenomenon in the pesticide industry, particularly affecting resource-intensive and overproduced products like glyphosate and phosphoric acid pesticides [2][5]. - The cancellation of the 9% export tax rebate will increase the offshore costs of related products, as domestic glyphosate production has tripled since 2021, leading to a significant price drop and compressed profit margins [2][5]. - The adjustment encourages a transition towards formulation and high-end products, avoiding raw pesticide exports and promoting deep-processing products [2][5]. Group 2: Market Trends and Future Outlook - In 2024, China's pesticide formulation export value is projected to reach $8.999 billion, an 11% increase from the previous year, indicating a shift in overseas market demand from low-end raw materials to high-value formulations [2][5]. - The core competitiveness of formulation exports lies in overseas registration qualifications, formulation technology, and brand building, which are strengths of leading companies and set the stage for industry consolidation [2][5]. - The cancellation of tax rebates may lead to a surge in overseas orders in the short term, potentially causing a temporary price increase for glyphosate and related products, but the industry is expected to undergo significant restructuring in the medium to long term [3][8]. Group 3: Comparison with Solar Industry - Similar to the solar industry, where export tax rebates are being reduced to combat low-price competition, the pesticide industry is also expected to see a shift from cost-based competition to value-based competition [3][8]. - The solar industry, which holds over 90% of global production capacity, has faced issues of domestic companies selling products at unsustainable prices, leading to a need for industry consolidation and innovation [3][6].

（文章来源：证券日报） 证券日报网讯 1月15日，贝斯美发布公告称，公司预计2025年度归属于上市公司股东的净利润为2，368 万元至3，406万元，上年同期为-3，286.46万元，比上年同期增长172.05%至203.64%。 ...

业内人士指出，《"十四五"全国农药产业发展规划》此前已明确指出要支持发展高效低风险新型化学农 药，大力发展生物农药。面对政策信号以及市场对绿色化学品需求的持续攀升，贝斯美凭借技术壁垒与 全链条环保升级的先发优势，继续加大研发创新投入，推动产品结构持续优化升级，展现出较强的经营 韧性。 展望未来，贝斯美表示，公司将继续坚定不移地推进精细化管理，持续提升运营效率，以管理赋能、以 创新驱动，持续巩固增长优势、拓宽发展空间。 1月15日晚间，贝斯美（300796）发布2025年度业绩预告。报告期内，公司预计实现归母净利润为2368 万元至3406万元，较去年同期同比增长172.05%至203.64%；实现扣非净利润1906万元至2737万元，较 去年同期同比增长152.89%至175.95%。 针对此次业绩变动原因，贝斯美表示，公司始终坚守"产业聚焦、技术创新、安环保障、规范运营"的核 心宗旨，以战略定力主动破局、稳健前行。一方面，公司深化"强链、延链"战略部署，推动产品结构持 续优化升级，与此同时，公司前期在新产品研发与国际化贸易渠道建设上的精准布局逐步落地，成效持 续释放，驱动扣非归母净利润转正并实现大幅增长，其 ...

证券日报网讯1月15日，中农联合（003042）在互动平台回答投资者提问时表示，公司作为原药制剂一 体化的农药生产企业，具备产业链协同优势，在新烟碱类农药产品的研发、生产及销售方面积累了丰富 的经验，吡虫啉原药、啶虫脒原药、哒螨灵原药、烯啶虫胺原药产销量均居国内前列。农药市场产品价 格受需求、供给和竞争等多种因素共同影响。面对激烈的市场竞争，公司将坚持聚焦主业，不断夯实经 营管理基础，积极加强市场开拓，灵活调整销售策略，深入推进降本增效，努力提升核心竞争力与经营 业绩。 ...